Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2011

Lilly to Use ArGEN-X Technology for mAb R&D

  • arGEN-X and Eli Lilly have agreed to discover and develop therapeutic antibody products against targets submitted by Lilly. arGEN-X will receive license fees and research funding as well as potential milestone payments.

    arGEN-X will generate novel human mAb candidates that act on diverse functional sites on Lilly targets using using its Simple Antibody platform. Lilly will have the option to select the most promising mAb candidates to take forward into preclinical and clinical development and potential commercialization.

    The Simple Antibody technology generates antibodies that do not need in vitro affinity maturation. It is based on the discovery that the binding sites of conventional four-chain antibodies in immunized Camelids have phenomenal functional attributes and comprise sequences and structures that are effectively human. Candidates generated on the platform have the closest possible homology to human germline sequence and the ideal human constant region isotype for functional performance, according to the company.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »